What does Theravance Biopharma do?
Theravance Biopharma, Inc. trades as TBPH on the Nasdaq Global Market. Incorporated in the Cayman Islands and operating mainly in the United States and Ireland, it has narrowed from broad drug development into a respiratory commercial asset, a large cash balance, milestone rights and a pending Zymeworks acquisition.
Which products and economic interests define the company?
The official company overview emphasizes medicines that make a difference. Economically, YUPELRI now dominates, making partner execution, patent life, COPD demand and transaction completion the central research questions.
How does Theravance Biopharma make money, and which assets matter most?
Viatris records U.S. YUPELRI net sales; Theravance receives 35% of U.S. profit or loss after shared commercial costs. Reported collaboration revenue is therefore a net partnership amount, not gross product sales. Analysts should track total brand sales, pricing and profitability alongside Theravance revenue.
| Economic stream | Mechanism | FY2025 evidence | Analytical implication |
|---|---|---|---|
| Viatris collaboration | 35% U.S. YUPELRI profit-and-loss share | $75.0M recognized revenue | Recurring core stream, but dependent on Viatris pricing, manufacturing and community execution. |
| YUPELRI milestones | Sales and regulatory payments | $25.0M U.S. sales milestone and $7.5M China approval milestone | Useful cash inflows, but more episodic than collaboration revenue. |
| China economics | Low double-digit tiered royalties plus milestones | Approval achieved in June 2025; up to $45.0M additional disclosed milestones remained at year-end | International upside exists, but timing and launch execution sit with Viatris. |
| TRELEGY residual rights | Contingent sales-based milestones after royalty monetization | $50.0M 2025 milestone recognized; up to $100.0M tied to 2026 sales | Material value, yet non-recurring and threshold-dependent. |
What did the 2025 revenue mix look like?
The key tension is recurring versus episodic value. YUPELRI collaboration revenue can compound with demand and pricing, while milestones can temporarily inflate earnings and cash flow. Sustainable brand economics should be separated from monetization gains and threshold payments.
What did Theravance Biopharma’s latest quarter show?
The first-quarter 2026 results showed YUPELRI U.S. net sales of $62.4M, up 7%. Customer demand rose 4% and hospital dose pull-through 19%. Theravance’s implied 35% share was $21.9M before shared commercial-cost adjustments.
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Viatris collaboration revenue | $17.7M | $15.4M | 15% growth, faster than YUPELRI net sales because of mix and shared-cost effects. |
| R&D expense | $5.8M | $11.5M | Down roughly half as CYPRESS wound down and restructuring began. |
| SG&A expense | $17.7M | $18.4M | Only modestly lower in Q1; management expected larger savings later in 2026. |
| Restructuring expense | $3.6M | Not applicable | Included $2.6M cash and $1.0M non-cash costs. |
| Cash and marketable securities | $394.7M | $130.9M | Boosted by the 2025 royalty sale and $75.0M of milestones received in Q1 2026. |
The latest Form 10-Q supported at least twelve months of liquidity. Q1 was transitional: commercial economics improved before the full restructuring benefit arrived.
Which strategic turning points shaped Theravance Biopharma today?
Theravance repeatedly converted respiratory intellectual property into partnerships, royalties, milestones and cash. A strategic review then accelerated simplification after a pivotal clinical failure.
-
2014Theravance Biopharma became an independent public company through a spin-off. The separation left it with drug-development capabilities and economic interests tied to respiratory products.
-
2015The company entered the revefenacin development and commercialization collaboration with Mylan, now Viatris. That agreement still determines how YUPELRI revenue, costs and control are shared.
-
2018–2019The FDA approved YUPELRI in November 2018 and the U.S. launch followed in 2019. This created the commercial franchise that now supports the company’s recurring economics.
-
2022Theravance sold its 85% economic interest in TRELEGY royalty rights to Royalty Pharma for about $1.11B upfront while retaining selected milestones and outer-year value.
-
2024The board formed an independent Strategic Review Committee to evaluate ways to unlock value across YUPELRI, ampreloxetine and TRELEGY-related assets.
-
2025Theravance sold its remaining TRELEGY royalty interest to GSK for $225.0M, retained milestone rights, and received YUPELRI approval in China through Viatris.
-
March 2026The Phase 3 CYPRESS study of ampreloxetine did not meet its primary endpoint. Management began winding down R&D and targeted a roughly 60% reduction in operating expenses.
-
June 2026Theravance agreed to be acquired by Zymeworks for $17.00 per share in cash plus an ampreloxetine CVR, subject to shareholder and regulatory approvals.
What did the CYPRESS failure change?
The March 2026 CYPRESS announcement removed the main internal pipeline catalyst. R&D became a cost base to unwind, shifting valuation toward YUPELRI cash flows, net cash, tax attributes, TRELEGY milestones and residual ampreloxetine optionality.
Why is YUPELRI the economic core of Theravance Biopharma?
YUPELRI addresses a defined COPD delivery need. It is a once-daily nebulized LAMA, whereas many nebulized bronchodilators require three or four daily doses. Nebulization can help patients limited by age, dexterity, inspiratory flow or disease severity, creating a differentiated niche rather than broad COPD dominance.
What makes the franchise defensible?
Defenses include product fit, hospital specialization, Viatris infrastructure and patents. The last listed YUPELRI patent expires in October 2039. Generic settlements generally permit licensed entry on April 23, 2039, including the final Mankind settlement in March 2026, subject to customary exceptions.
The official YUPELRI product site provides prescribing information. Investment relevance depends on adoption, net price and hospital pull-through within nebulized COPD care.
Who competes with Theravance Biopharma, and what is its market position?
Theravance competes against companies with broader respiratory portfolios. YUPELRI is the only approved nebulized LAMA after Lonhala Magnair’s 2023 withdrawal, but clinicians can choose short-acting nebulizers, handheld maintenance therapies, triple therapy, phenotype-specific biologics and newer nebulized products.
| Competitive option | Position versus YUPELRI | Pressure or complement | Key distinction |
|---|---|---|---|
| Short-acting nebulized bronchodilators | Primary practical competitor | Pressure | Typically dosed three to four times daily versus once-daily YUPELRI. |
| Merck Ohtuvayre | Nebulized PDE3/PDE4 maintenance medicine | Potential complement and budget competitor | Often positioned as add-on treatment to standard care that includes LAMA plus LABA. |
| Sanofi/Regeneron Dupixent | Biologic for selected uncontrolled COPD patients | Adjacent pressure | Targets a Type 2 inflammation phenotype rather than the same delivery niche. |
| GSK Nucala | Add-on biologic for eosinophilic COPD | Adjacent pressure | Serves a defined phenotype after inadequate control on conventional therapy. |
Where does Theravance sit strategically?
This is a defensible niche, not a scale moat. Payers retain buyer power, while a single API supplier, drug-product supplier and warehouse create supplier risk. Viatris adds commercial reach but also concentrates partner dependence.
How strong are Theravance Biopharma’s balance sheet and cash-flow prospects?
The balance sheet is the clearest strength. A $225.0M royalty monetization in 2025 and $75.0M of milestone cash in Q1 2026 lifted liquidity well above the shrinking operating cost base.
| Financial measure | FY2025 | FY2024 | Quality assessment |
|---|---|---|---|
| Total revenue | $107.5M | $64.4M | Growth was boosted by $32.5M of milestone revenue. |
| Net income (loss) | $105.9M | ($56.4M) | FY2025 profit was dominated by royalty-sale gains and milestones, not only recurring operations. |
| Operating cash flow | $238.5M | ($11.5M) | Strong, but heavily influenced by monetization proceeds and working-capital timing. |
| R&D expense | $37.4M | $37.6M | The major decline was expected after year-end as the R&D function wound down. |
| SG&A expense | $73.7M | $69.2M | The restructuring targeted a roughly 50% reduction in G&A employees. |
How should profitability be interpreted?
FY2025 net income is not a normalized earnings base. The durable test is whether YUPELRI economics exceed reduced corporate costs. Management’s $60M–$70M annualized cash-flow target suggested they could, but the merger shifts attention to closing, retained cash and CVR terms.
Who owns Theravance Biopharma stock, and why does governance matter?
Theravance has one ordinary share class and one vote per share. Its concentrated institutional base therefore matters directly to the Zymeworks vote and to judgments about realizing YUPELRI, cash, milestone, tax-attribute and ampreloxetine value.
| Holder or group | Shares | Ownership | Why it matters |
|---|---|---|---|
| Madison Avenue Partners | 9,511,150 | 18.46% | Largest disclosed holder; a major vote in any merger approval. |
| Weiss Asset Management | 7,457,060 | 14.48% | Large concentrated stake increases scrutiny of transaction value and closing terms. |
| Newtyn Management | 4,300,000 | 8.35% | Another material institutional block in a one-share-one-vote structure. |
| BlackRock | 3,235,696 | 6.28% | Passive and institutional stewardship adds conventional governance influence. |
| Directors and executives as a group | 4,065,980 | 7.65% | Management has economic alignment but not voting control. |
How did the board structure affect the strategic outcome?
The 2026 proxy statement says the independent Strategic Review Committee met 13 times in 2025. Rick E Winningham, chief executive since the 2014 spin-off, beneficially owned 3.87% as of April 13, 2026.
What opportunities could still change Theravance Biopharma’s value?
The pending acquisition narrows the opportunity set, but several operating and contingent items still affect value before closing.
What is the largest near-term operating opportunity?
The clearest opportunity is YUPELRI growth on a smaller cost base. Net sales rose from $238.6M in 2024 to $266.6M in 2025, while the planned post-Q3 2026 organization focused on commercial support rather than broad discovery.
What risks could weaken Theravance Biopharma’s outlook?
Risks are concentrated: one commercial product, one major partner, single-source supply, patent protection and a signed merger. Large cash reserves reduce financing risk, not operating or transaction risk.
| Risk | Financial line affected | Current evidence | What to monitor |
|---|---|---|---|
| Merger closing risk | Equity value and transaction costs | Closing expected in H2 2026, subject to shareholder and regulatory approvals | Merger proxy, vote date, regulatory clearance and termination provisions. |
| YUPELRI concentration | Collaboration revenue and cash flow | All Q1 2026 reported revenue came from the Viatris collaboration | Net sales, demand, pricing, hospital pull-through and reimbursement. |
| Partner dependence | Revenue, manufacturing and commercialization | Viatris holds the NDA and controls manufacturing, pricing and community promotion | Commercial execution, priorities, disputes and compliance. |
| Supply concentration | Product availability and revenue | Single API supplier, drug-product supplier and warehouse disclosed | Quality events, capacity, regulatory inspections and inventory continuity. |
| Generic and patent risk | Long-term pricing and profit share | Settlements generally permit licensed launch in April 2039 | Any exceptions, new challenges and patent enforcement outcomes. |
| CVR uncertainty | Contingent shareholder value | CYPRESS failed its primary endpoint | Regulatory feedback, licensing interest, costs and net-proceeds definition. |
Which risk is most material now?
After the June 29, 2026 acquisition agreement, closing became the central near-term risk. Failure would restore a standalone valuation based on YUPELRI, cash, restructuring and uncertain contingent assets.
Why does Theravance Biopharma’s business model matter for valuation?
A conventional high-growth biotech DCF fits poorly in mid-2026. Theravance has a signed cash acquisition, a CVR, substantial cash, a partnered product, milestone rights and a shrinking organization. Analysis is closer to sum-of-the-parts and merger arbitrage.
| Valuation driver | Relevant evidence | DCF or transaction treatment | Main sensitivity |
|---|---|---|---|
| Cash consideration | $17.00 per share; approximately $929M equity value | Discount for closing probability and time to completion | Shareholder approval, regulation and merger terms. |
| YUPELRI economics | $266.6M FY2025 net sales; 35% U.S. profit share | Forecast sales growth, net price, shared costs and patent life | Demand, competition, partner execution and generic timing. |
| Cash and securities | $394.7M at March 31, 2026 | Adjust for restructuring costs, transaction fees and operating cash changes | Cash burn or generation before closing. |
| TRELEGY milestone | Up to $100.0M tied to FY2026 sales | Probability-weight the threshold payment | Reported global sales and contractual interpretation. |
| Ampreloxetine CVR | 80% of net monetization proceeds for ten years | Treat as high-uncertainty contingent optionality | Regulatory path, buyer interest, costs and timing. |
| Irish tax attributes | Approximately $2.6B highlighted by management | Value only to the extent legally usable against future taxable income | Tax structure, ownership-change limits and jurisdictional rules. |
What is the central valuation trade-off?
The offer is 22% above the March 3, 2026 close and 10% above the subsequent volume-weighted average price. Those premiums do not replace asset analysis: compare the offer with net cash, YUPELRI cash flow, milestone probability, tax usability, expenses and CVR value.
What is the key takeaway from Theravance Biopharma analysis?
Theravance is now a concentrated respiratory economics story, not primarily a pipeline biotech. YUPELRI’s once-daily nebulized profile, rising sales, 35% U.S. profit share and licensed generic timing in 2039 support durability. Product, partner, supply and payer concentration remain the counterweights.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.